Patients with metastatic colorectal cancer (mCRC) with This study utilized a de-identified mCRC clinicogenomic database from ∼280 US cancer clinics between March 2014 and April 2023. We examined real- Show more
Patients with metastatic colorectal cancer (mCRC) with This study utilized a de-identified mCRC clinicogenomic database from ∼280 US cancer clinics between March 2014 and April 2023. We examined real-world progression-free survival (rwPFS) and overall survival (rwOS) between patients with and those without pre-specified genomic alterations (PSGAs) by Cox models and an adjusted risk score. Genomic alterations were also compared between samples collected before and after EGFR mAb therapy. Nearly, one-third of microsatellite stable (MSS) Detection of genomic resistance alterations in MSS Show less